FR3039166B1 - Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes - Google Patents

Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes Download PDF

Info

Publication number
FR3039166B1
FR3039166B1 FR1557020A FR1557020A FR3039166B1 FR 3039166 B1 FR3039166 B1 FR 3039166B1 FR 1557020 A FR1557020 A FR 1557020A FR 1557020 A FR1557020 A FR 1557020A FR 3039166 B1 FR3039166 B1 FR 3039166B1
Authority
FR
France
Prior art keywords
proplaquets
cd41dim
carriing
megacaryocyte
plaquettes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1557020A
Other languages
English (en)
Other versions
FR3039166A1 (fr
Inventor
Catherine STRASSEL
Christian Gachet
Francois Lanza
Nathalie BROUARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Strasbourg
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Francais du Sang Ets
Universite de Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1557020A priority Critical patent/FR3039166B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Francais du Sang Ets, Universite de Strasbourg filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to CA2993596A priority patent/CA2993596A1/fr
Priority to CN201680047758.8A priority patent/CN107922924B/zh
Priority to JP2018503184A priority patent/JP7068162B6/ja
Priority to PCT/EP2016/067594 priority patent/WO2017013262A1/fr
Priority to AU2016296920A priority patent/AU2016296920B2/en
Priority to EP16742302.9A priority patent/EP3334822A1/fr
Priority to US15/747,023 priority patent/US11236303B2/en
Publication of FR3039166A1 publication Critical patent/FR3039166A1/fr
Application granted granted Critical
Publication of FR3039166B1 publication Critical patent/FR3039166B1/fr
Priority to JP2021121618A priority patent/JP2021177774A/ja
Priority to US17/547,444 priority patent/US20220135946A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2309—Interleukin-9 (IL-9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR1557020A 2015-07-23 2015-07-23 Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes Active FR3039166B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR1557020A FR3039166B1 (fr) 2015-07-23 2015-07-23 Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes
US15/747,023 US11236303B2 (en) 2015-07-23 2016-07-22 CD34+CD41DIM megakaryocytes progenitors and uses thereof for producing proplatelet-bearing MKs and/or platelets
JP2018503184A JP7068162B6 (ja) 2015-07-23 2016-07-22 Ｃｄ３４＋ｃｄ４１ｄｉｍ巨核球前駆細胞及び血小板前駆細胞を有するｍｋ及び／又はその血小板を製造するためのその使用。
PCT/EP2016/067594 WO2017013262A1 (fr) 2015-07-23 2016-07-22 Cellules progénitrices de mégacaryocytes cd34+cd41dim et utilisations associées pour la production de mégacaryocytes et/ou de plaquettes portant des proplaquettes
AU2016296920A AU2016296920B2 (en) 2015-07-23 2016-07-22 CD34+CD41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing MKs and/or platelets
EP16742302.9A EP3334822A1 (fr) 2015-07-23 2016-07-22 Cellules progénitrices de mégacaryocytes cd34+cd41dim et utilisations associées pour la production de mégacaryocytes et/ou de plaquettes portant des proplaquettes
CA2993596A CA2993596A1 (fr) 2015-07-23 2016-07-22 Cellules progenitrices de megacaryocytes cd34+cd41dim et utilisations associees pour la production de megacaryocytes et/ou de plaquettes portant des proplaquettes
CN201680047758.8A CN107922924B (zh) 2015-07-23 2016-07-22 巨核细胞祖细胞及其产生带有前血小板的mk和/或血小板的应用
JP2021121618A JP2021177774A (ja) 2015-07-23 2021-07-26 Ｃｄ３４＋ｃｄ４１ｄｉｍ巨核球前駆細胞及び血小板前駆細胞を有するｍｋ及び／又はその血小板を製造するためのその使用。
US17/547,444 US20220135946A1 (en) 2015-07-23 2021-12-10 Cd34+cd41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing mks and/or platelets

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1557020 2015-07-23
FR1557020A FR3039166B1 (fr) 2015-07-23 2015-07-23 Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes

Publications (2)

Publication Number Publication Date
FR3039166A1 FR3039166A1 (fr) 2017-01-27
FR3039166B1 true FR3039166B1 (fr) 2018-10-26

Family

ID=55072774

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1557020A Active FR3039166B1 (fr) 2015-07-23 2015-07-23 Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes

Country Status (8)

Country Link
US (2) US11236303B2 (fr)
EP (1) EP3334822A1 (fr)
JP (2) JP7068162B6 (fr)
CN (1) CN107922924B (fr)
AU (1) AU2016296920B2 (fr)
CA (1) CA2993596A1 (fr)
FR (1) FR3039166B1 (fr)
WO (1) WO2017013262A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3039166B1 (fr) 2015-07-23 2018-10-26 Institut National De La Sante Et De La Recherche Medicale Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes
US20210054336A1 (en) * 2018-01-05 2021-02-25 Platelet Biogenesis, Inc. Compositions and Methods for Producing Megakaryocytes
FR3101885A1 (fr) 2019-10-11 2021-04-16 Etablissement Français Du Sang Systeme pour la liberation de plaquettes et procede de liberation de plaquettes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024875A2 (fr) * 2002-09-13 2004-03-25 The Board Of Trustees Of The Leland Stanford Junior University Cellule souche mammifere de megakaryocytes
JPWO2009119105A1 (ja) 2008-03-28 2011-07-21 国立大学法人 東京大学 ＧＰＩｂα＋ＧＰＶ＋ＧＰＶＩ＋血小板のインビトロ調製法
WO2012129109A2 (fr) 2011-03-18 2012-09-27 New York Blood Center, Inc. Production de mégacaryocytes et de plaquettes à partir de cellules souches
US9920295B2 (en) 2012-02-21 2018-03-20 The Trustees Of The University Of Pennsylvania Bioreactor for isolation of rare cells and methods of use
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
GB201220937D0 (en) * 2012-11-21 2013-01-02 Airbus Uk Ltd Modular structural assembly
WO2014138485A1 (fr) * 2013-03-08 2014-09-12 Irm Llc Production de plaquettes ex vivo à partir de cellules souches hématopoïétiques et leur produit
FR3039166B1 (fr) * 2015-07-23 2018-10-26 Institut National De La Sante Et De La Recherche Medicale Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes

Also Published As

Publication number Publication date
FR3039166A1 (fr) 2017-01-27
AU2016296920A1 (en) 2018-02-15
CN107922924A (zh) 2018-04-17
EP3334822A1 (fr) 2018-06-20
CN107922924B (zh) 2022-01-11
JP2021177774A (ja) 2021-11-18
US20180216068A1 (en) 2018-08-02
JP7068162B2 (ja) 2022-05-16
US11236303B2 (en) 2022-02-01
US20220135946A1 (en) 2022-05-05
AU2016296920B2 (en) 2022-05-26
JP7068162B6 (ja) 2023-12-20
CA2993596A1 (fr) 2017-01-26
WO2017013262A1 (fr) 2017-01-26
JP2018519845A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
HK1254337A1 (zh) April的抗體分子及其用途
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA55044A (fr) Hétéromultimères alk4:actriib et leurs utilisations
MA43417A (fr) Agonistes améliorés du récepteur de l'apéline (apj) et leurs utilisations
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
MA46472A (fr) Hétéromultimères alk4:actriib et leurs utilisations
FR3021533B1 (fr) Composition cosmetique de type gel
MA43567A (fr) Anticorps pacap et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA46036A (fr) Anticorps anti-vegf-a et anti-ang2 et leurs utilisations
MA46945A (fr) Exopolysaccharides et leurs utilisations
FR3018191B1 (fr) Utilisations cosmetiques de la swertiamarine
MA50678A (fr) Molécules de liaison spécifiques de l'il-21 et leurs utilisations
MA41864A (fr) Variants de protoxine ii et leurs méthodes d'utilisation
MA44968A (fr) Esters d'oxaborole et leurs utilisations
MA42546A (fr) Combinaisons d'inhibiteur de la tyrosine kinase de bruton et leurs utilisations
MA45411A (fr) Compositions antimalariques et leurs utilisations
FR3039166B1 (fr) Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes
MA41022A (fr) Ciblage lysosomial et utilisations correspondantes
DK3440752T3 (da) Indsatshalvdel og indsatsblok omfattende to af nævnte indsatshalvdele
DK3300482T3 (da) Brug af prg4 til at forbedre dynamisk synsstyrke og højere ordens aberrationer

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

EXTE Extension to a french territory

Extension state: PF

PLSC Publication of the preliminary search report

Effective date: 20170127

PLFP Fee payment

Year of fee payment: 3

TQ Partial transmission of property

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20180319

Owner name: UNIVERSITE DE STRASBOURG, FR

Effective date: 20180319

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9